Morphosys shares fall after dermatitis treatment flops
Reuters: Health
German biotech company Morphosys halted development of an experimental atopic dermatitis treatment that analysts had pinned hopes of blockbuster sales potential on, sending its shares down as much as 6.8% on Tuesday.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment